|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Localization of the FOP-FGFR1 fusion kinase to centriolar satellites may be relevant to myeloproliferative neoplasm disease progression.
|
23554904 |
2013 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
|
15448205 |
2004 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Protein tyrosine kinase abnormalities, including translocations or mutations involving ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB, and FGFR1, have been used as the basis for classifying myeloproliferative neoplasms (MPN).
|
20626469 |
2010 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Rearrangements of the genes encoding the fibroblast growth factor receptor 1 (FGFR1) and platelet-derived growth factor receptors (PDGFR) alpha or beta receptor tyrosine kinases are found in a rare but important subset of patients with atypical myeloproliferative disorders that are usually but not always associated with eosinophilia.
|
18566537 |
2008 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Taking its high specificity for FGFRs into account, infigratinib could be beneficial for EMS patients and should be further investigated for the treatment of myeloproliferative neoplasms with FGFR1 abnormalities.
|
26391436 |
2016 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is an aggressive, atypical stem cell myeloproliferative disorder associated with chromosome translocations that disrupt and constitutively activate FGFR1 by fusion to diverse partner genes.
|
17698633 |
2007 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
CTD_human |
The 8p11 myeloproliferative syndrome is a rare, aggressive myeloproliferative neoplasm characterized by constitutively active FGFR1 fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation.
|
22875613 |
2013 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3): a novel translocation involving the FGFR1 gene.
|
11122115 |
2000 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The introduction of JAK2 mutation testing has changed dramatically the diagnostic algorithms for myeloproliferative neoplasms (MPNs) but there is still a place for conventional cytogenetic analysis in the initial work-up of MPN cases, particularly as this group of myeloid disorders has been expanded to include chronic eosinophilic leukaemia and myeloid neoplasms with abnormalities of the PDGFRA, PDGFRB, and FGFR1 genes.
|
21431636 |
2011 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The KG-1a cell line is developed from a human stem cell myeloproliferative neoplasm as the result of intragenic disruption and a chromosomal translocation of the FGFR1 gene and the FGFR1OP2 gene encoding a protein of unknown function called FOP2 (FGFR1 Oncogene Partner 2).
|
21745565 |
2011 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The t(8;13) translocation, found in a rare and aggressive type of stem cell myeloproliferative disorder, leads to the generation of a fusion protein between the N-terminal gene product of fused in myeloproliferative disorders (FIM)/ZNF198 and the fibroblast growth factor receptor 1 (FGFR1) kinase domain.
|
14672707 |
2004 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The ZNF198/FGFR1 fusion gene in atypical myeloproliferative disease produces a constitutively active cytoplasmic tyrosine kinase, unlike ZNF198 which is normally a nuclear protein.
|
17027752 |
2006 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Three of the four FGFR1-rearranged cases were associated with myeloproliferative neoplasms but none, including the two with sole 8p11.2, displayed the typical phenotype for stem cell leukemia/lymphoma (SCLL) and only one had eosinophilia; the fourth case had AML-M4.
|
20143402 |
2010 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We describe a case of coexisting BCR-ABL negative myeloproliferative disorder and precursor T-cell lymphoblastic lymphoma associated with t(8;13) involving FGFR1 at 8p11 in a 14-year-old boy who presented with generalized lymphadenopathy and an abdominal mass.
|
16777224 |
2007 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We report herein a rare case of a t(1;8)(q25;p11.2) with a TPR-FGFR1 rearrangement, in which the patient presented with myeloproliferative neoplasm-like symptoms and T-lymphoblastic lymphoma.
|
25037443 |
2014 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
ZNF198 is fused with FGFR1 in an atypical myeloproliferative disease that results in constitutive activation of the kinase domain and mislocalization to the cytoplasm.
|
15975576 |
2005 |